Recombinant human IL-10
-
Cat.code:
rcyc-hil10NEW
- Documents
ABOUT
Human IL-10 protein - Mammalian cell-expressed, tag-free, carrier-free
Recombinant human IL-10 is a high-quality and biologically active cytokine, validated using proprietary IL-10 reporter cells. This founding member of the IL-10 cytokine family is produced in HEK cells to ensure protein glycosylation and bona fide 3D structure.
Recombinant human IL-10 can be used together with HEK-Blue™ IL-10 cells for the screening of inhibitory molecules, such as therapeutic monoclonal antibodies (see figures).
Key features
- Each lot is validated using HEK-Blue™ IL-10 cells
- Endotoxin ≤ 0.01 EU/µg
- 0.2 µm sterile-filtered
Applications
- Standard for IL-10 detection and quantification
- Screening and release assays for antibodies blocking IL-10 signaling
- Screening and release assays for engineered IL-10
Interleukin 10 (IL-10) is an anti-inflammatory cytokine with a crucial role in preventing inflammatory and autoimmune pathologies. While it is known for its immunosuppressive role in conditions like inflammatory bowel disease and chronic infections, it also shows a surprising protective effect in cancer.
All InvivoGen products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
P22301
100 μg/ml in water
Phosphate buffer saline (pH 7.4), 5% saccharose
0.2 µm filtration
The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.
Cellular assays (tested), ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Recombinant human IL-10
-
Cat code:rcyc-hil10
-
Quantity:10 µg
1.5 ml endotoxin-free water
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Interleukin 10 (IL-10) is the founding member of the IL-10 cytokine family, which comprises IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A (IFN-λ2), IL-28B (IFN-λ3), and IL-29 (IFN-λ1)1. IL-10 was originally depicted as a key mediator of anti-inflammatory responses. While the immunosuppressive action of IL-10 is illustrated by its genetic association with inflammatory bowel disease or its upregulated expression in chronic infections, an unanticipated IL-10 protective role has been reported in cancer [1].
IL-10 also plays important homeostatic roles in non-immune cells, including neurons, adipocytes, and epithelial cells [1]. The manipulation of IL-10 production and signaling has thus become an attractive therapeutic strategy [2].
Upon IL-10 binding, the IL-10Rα chain oligomerizes with the IL-10Rβ chain. This, in turn, allows the phosphorylation of JAK1 (Janus kinase 1) and TyK2 (Tyrosine kinase 2), and the subsequent activation of STAT3 (Signal transducer and activator of transcription 3) [1]. Importantly, STAT3 is also activated downstream of other cytokine receptors. How the cells trigger distinct and specific gene expression in response to cytokine signaling through the same transcription factor is not fully understood yet [1].
1. Saraiva M, et al., 2019. Biology and therapeutic potential of interleukin-10. J. Exp. Med. doi: 10.1084/jem.20190418.
2. Ouyang W & O’Garra A, 2019. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 50:871-91.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
